220 related articles for article (PubMed ID: 11896119)
81. Functional myocardial impairment in children treated with anthracyclines for cancer.
Yeung ST; Yoong C; Spink J; Galbraith A; Smith PJ
Lancet; 1991 Apr; 337(8745):816-8. PubMed ID: 1672914
[TBL] [Abstract][Full Text] [Related]
82. Late effects of anthracycline therapy in childhood in relation to the function of the heart at rest and under physical stress.
Lang D; Hilger F; Binswanger J; Andelfinger G; Hartmann W
Eur J Pediatr; 1995 May; 154(5):340-5. PubMed ID: 7641762
[TBL] [Abstract][Full Text] [Related]
83. A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells.
El-Kareh AW; Secomb TW
Neoplasia; 2000; 2(4):325-38. PubMed ID: 11005567
[TBL] [Abstract][Full Text] [Related]
84. Doxorubicin cardiotoxicity in children.
Biancaniello T; Meyer RA; Wong KY; Sager C; Kaplan S
J Pediatr; 1980 Jul; 97(1):45-50. PubMed ID: 7381647
[TBL] [Abstract][Full Text] [Related]
85. Omega 3 fatty acids can reduce early doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukemia.
El Amrousy D; El-Afify D; Khedr R; Ibrahim AM
Pediatr Blood Cancer; 2022 Jul; 69(7):e29496. PubMed ID: 34842343
[TBL] [Abstract][Full Text] [Related]
86. Late recovery of ventricular function in children with idiopathic dilated cardiomyopathy.
Lewis AB
Am Heart J; 1999 Aug; 138(2 Pt 1):334-8. PubMed ID: 10426848
[TBL] [Abstract][Full Text] [Related]
87. Doxorubicin concentrations in bone tumour-relevant tissues after bolus and continuous infusion: a randomized porcine microdialysis study.
Jørgensen AR; Bue M; Hanberg P; Petersen EK; Harlev C; Hansen J; Baad-Hansen T; Safwat A; Stilling M
Cancer Chemother Pharmacol; 2024 Jun; 93(6):555-564. PubMed ID: 38332155
[TBL] [Abstract][Full Text] [Related]
88. Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin.
Li J; Chang HM; Banchs J; Araujo DM; Hassan SA; Wagar EA; Yeh ETH; Meng QH
Cardiooncology; 2020; 6():1. PubMed ID: 32154027
[TBL] [Abstract][Full Text] [Related]
89. Congestive heart failure due to adriamycin cardiotoxicity: its natural history in children.
Goorin AM; Borow KM; Goldman A; Williams RG; Henderson IC; Sallan SE; Cohen H; Jaffe N
Cancer; 1981 Jun; 47(12):2810-6. PubMed ID: 6942908
[TBL] [Abstract][Full Text] [Related]
90. Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group.
Chow EJ; Aplenc R; Vrooman LM; Doody DR; Huang YV; Aggarwal S; Armenian SH; Baker KS; Bhatia S; Constine LS; Freyer DR; Kopp LM; Leisenring WM; Asselin BL; Schwartz CL; Lipshultz SE
Cancer; 2022 Feb; 128(4):788-796. PubMed ID: 34644414
[TBL] [Abstract][Full Text] [Related]
91. A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography.
Schwarz ER; Pollick C; Dow J; Patterson M; Birnbaum Y; Kloner RA
Cardiovasc Res; 1998 Jul; 39(1):216-23. PubMed ID: 9764201
[TBL] [Abstract][Full Text] [Related]
92. Transcriptional analysis of doxorubicin-induced cardiotoxicity.
Yi X; Bekeredjian R; DeFilippis NJ; Siddiquee Z; Fernandez E; Shohet RV
Am J Physiol Heart Circ Physiol; 2006 Mar; 290(3):H1098-102. PubMed ID: 16243910
[TBL] [Abstract][Full Text] [Related]
93. Immunology of infusion reactions in the treatment of patients with acute lymphoblastic leukemia.
Asselin B
Future Oncol; 2016 Jul; 12(13):1609-21. PubMed ID: 27086555
[TBL] [Abstract][Full Text] [Related]
94. Clinical pharmacology of continuous infusion doxorubicin.
Sweatman TW; Lokich JJ; Israel M
Ther Drug Monit; 1989; 11(1):3-9. PubMed ID: 2911850
[TBL] [Abstract][Full Text] [Related]
95. Late doxorubicin-associated cardiotoxicity in children. The possible role of intercurrent viral infection.
Ali MK; Ewer MS; Gibbs HR; Swafford J; Graff KL
Cancer; 1994 Jul; 74(1):182-8. PubMed ID: 8004574
[TBL] [Abstract][Full Text] [Related]
96. Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology Group.
Kopp LM; Womer RB; Schwartz CL; Ebb DH; Franco VI; Hall D; Barkauskas DA; Krailo MD; Grier HE; Meyers PA; Wexler LH; Marina NM; Janeway KA; Gorlick R; Bernstein ML; Lipshultz SE;
Cardiooncology; 2019; 5():15. PubMed ID: 32154021
[TBL] [Abstract][Full Text] [Related]
97. Cardiac arrhythmias in patients with small cell lung cancer and cardiac disease before, during and after doxorubicin administration. An evaluation of acute cardiotoxicity by continuous 24-hour Holter monitoring.
Raabe NK; Storstein L
Acta Oncol; 1991; 30(7):843-6. PubMed ID: 1662523
[TBL] [Abstract][Full Text] [Related]
98. Continuous infusion or bolus injection in cancer chemotherapy.
Carlson RW; Sikic BI
Ann Intern Med; 1983 Dec; 99(6):823-33. PubMed ID: 6197002
[TBL] [Abstract][Full Text] [Related]
99. Parameter estimation in longitudinal studies with outcome-dependent follow-up.
Lipsitz SR; Fitzmaurice GM; Ibrahim JG; Gelber R; Lipshultz S
Biometrics; 2002 Sep; 58(3):621-30. PubMed ID: 12229997
[TBL] [Abstract][Full Text] [Related]
100. Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion.
Quintana RA; Banchs J; Gupta R; Lin HY; Raj SD; Conley A; Ravi V; Araujo D; Benjamin RS; Patel S; Vadhan-Raj S; Somaiah N
Sarcoma; 2017; 2017():7495914. PubMed ID: 29081684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
